Sugi Predict

Sugi Predict / Compounds / SCHEMBL4094402

SCHEMBL4094402

SCHEMBL4094402

CC(C)Cc1nc(-c2ccc3[nH]nc(-c4ccc5cc(OCc6ccccn6)ccc5c4)c3c2)n[nH]1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FGFR4 P22455 1/20 0.43
▸ FGFR1 P11362 1/20 0.42
▸ TTK P33981 5/20 0.41
▸ HTT P42858 3/20 0.39
▸ SMN1; SMN2 Q16637 3/20 0.39
▸ LMNA P02545 3/20 0.39
▸ CSNK1D P48730 2/20 0.38
▸ KDM4E B2RXH2 2/20 0.38
▸ TDP1 Q9NUW8 2/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ NFKB1 P19838 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ NFKB2 Q00653 1/20 0.38
▸ RELA Q04206 1/20 0.38
▸ MAOA P21397 1/20 0.38
▸ NTRK1 P04629 2/20 0.37
▸ NTRK3 Q16288 1/20 0.37
▸ NTRK2 Q16620 1/20 0.37
▸ MAPK8 P45983 3/20 0.37
▸ TP53 P04637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4084459 0.88 FGFR4 (0.45) FGFR4FGFR1TTKHTTSMN1; SMN2
SCHEMBL4083523 0.84 CSNK1D (0.44) TTKCSNK1DNPC1RAB9A
SCHEMBL4079722 0.83 CSNK1D (0.60) FGFR4FGFR1TTKCSNK1DNTRK1
SCHEMBL13812057 0.83 ACHE (0.39) TTKCSNK1DMAPK8
SCHEMBL4094138 0.82 BRAF (0.42) TTKCSNK1DKDM4EMAOAMAPK8
SCHEMBL4083954 0.81 CSNK1D (0.51) FGFR4FGFR1CSNK1DNTRK1L3MBTL1
SCHEMBL4079750 0.81 CSNK1D (0.38) TTKCSNK1DNTRK1MAPK8
SCHEMBL4052564 0.79 CLK2 (0.52) FGFR1CSNK1DKDM4EMAPK8
SCHEMBL13812022 0.78 CSNK1D (0.41) TTKCSNK1DMAPK8
SCHEMBL4083165 0.78 CLK2 (0.53) FGFR1CSNK1DMAPK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2065383-A1 Indazole compounds and methods of use thereof as protein kinase inhibitors Signal Pharmaceuticals, Inc. (US) 2009-06-03 — — EP disclosed
EP-2065383-A1 Indazole compounds and methods of use thereof as protein kinase inhibitors Signal Pharmaceuticals, Inc. (US) 2009-06-03 — — EP disclosed
US-20090099178-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF BHAGWAT SHRIPAD S 2009-04-16 — — US disclosed
US-20090099178-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF BHAGWAT SHRIPAD S 2009-04-16 — — US disclosed
US-20090099178-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF BHAGWAT SHRIPAD S 2009-04-16 — — US disclosed
US-20060004043-A1 Indazole compounds and methods of use thereof BHAGWAT SHRIPAD S 2006-01-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099178-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF WNT3, WNT3A, WNK3 FGFR4 1491/4885FGFR1 827/4885TTK 401/4885
US-20060004043-A1 Indazole compounds and methods of use thereof WNT3, WNT3A, WNK3 FGFR4 1417/4885FGFR1 791/4885TTK 377/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.